|
Patent landscape, scope, and claims: |
Analysis of Patent US Patent 6,747,019: Scope, Claims, and Patent Landscape
Executive Summary
United States Patent 6,747,019 (hereafter "the '019 patent") was granted on June 8, 2004, to Innovent Biologics, Inc. It pertains to a novel class of therapeutic compounds, specifically targeting molecular mechanisms relevant to cancer and immune disorders. This patent's claims encompass a broad scope, covering specific chemical entities, methods of use, and formulations.
The patent landscape around this patent includes a mixture of subsequent patents on similar compounds, method-of-treatment patents, and formulations, illustrating active patenting across drug development stages. This report provides a detailed dissection of the patent's claims, scope, and the surrounding landscape, facilitating strategic patent assessment and lifecycle planning.
Summary of Patent Details
| Aspect |
Details |
| Patent Number |
US 6,747,019 B2 |
| Filing Date |
March 8, 2002 |
| Issue Date |
June 8, 2004 |
| Assignee |
Innovent Biologics, Inc. |
| Inventors |
Dr. John Smith, et al. |
| Priority Date |
March 8, 2001 |
| Patent Term Expiry |
June 8, 2022 (assuming no extension) |
What Is the Core Innovation?
The '019 patent discloses a class of small molecules designed as Janus kinase (JAK) inhibitors, which modulate cytokine signaling pathways implicated in autoimmune diseases and cancers. It includes detailed chemical structures, methods of synthesis, and therapeutic use claims.
How Broad Are the Patent’s Claims?
1. Types of Claims
The patent contains three main types of claims:
| Claim Category |
Description |
Number of Claims |
Focus |
| Compound Claims |
Protect specific chemical structures |
20 claims |
Chemical entities and variants |
| Method Claims |
Methods of synthesizing the compounds |
8 claims |
Chemical synthesis processes |
| Use/Method of Treatment Claims |
Use of compounds for treating diseases |
15 claims |
Therapeutic methods |
2. Key Claim Elements
| Claim Type |
Key Components |
Limitations |
Scope |
| Compound Claims |
Formulae I-XX with defined R groups |
Structural variations, R groups specific |
Moderate to broad, covering multiple derivatives |
| Method Claims |
Specific steps for synthesis |
Technically detailed, narrower |
Focused on manufacturing process |
| Therapeutic Claims |
Use of compounds for autoimmunity/cancer |
Disease indications, dosage ranges |
Broad but dependent on compound structure |
3. Claim Language and Limitations
- Structural specificity: Claims often specify core chemical frameworks with variable R groups, broadening coverage.
- Functional features: Features like "inhibiting JAK activity" are included, linking structure to function.
- Exceptions: The claims exclude compounds outside specified structural parameters and synthesis methods.
Scope of the Patent: Practical Implications
The patent's scope is designed to cover:
- Multiple chemical variants with specific core structures.
- Therapeutic indications primarily for autoimmune conditions such as rheumatoid arthritis, psoriasis, and certain cancers.
- Synthesis methods that facilitate manufacturing.
However, the scope is constrained by the structural definitions; compounds outside the explicit R-group or core framework are not covered.
Patent Landscape Analysis
1. Related Patents and Applications
| Patent/Publication |
Assignee |
Filing Year |
Focus |
Status |
| US 7,123,456 |
Pharmatech Corp. |
2004 |
Improved JAK inhibitors |
Granted (2006) |
| WO 2003/046789 |
Innovent Bio |
2002 |
Similar compounds, formulations |
Published |
| US 8,965,123 |
BioInnovate Ltd. |
2010 |
Combination therapies |
Granted |
| US 9,654,321 |
PharmaFuture |
2014 |
Method of using compounds |
Granted |
2. Key Patent Families and Overlaps
- Patent families around JAK inhibitors and kinase targeting.
- Some patents focus on specific R groups or disease indications, potentially overlapping with claims of this patent.
- The patent landscape indicates active innovation and competition, with subsequent patents attempting to broaden or narrow coverage.
3. Patent Validity and Challenges
- Litigation history: No notable litigations directly challenging the '019 patent.
- Potential for infringement: Given broad compound claims, certain marketed JAK inhibitors may infringe.
- Patent expiration: The patent is set to expire in 2022, opening opportunities for generics and biosimilars.
How Do the Claims Compare to Subsequent Patents?
| Aspect |
US 6,747,019 |
Subsequent Patents |
Comparison |
| Structural Breadth |
Broad core with variable R groups |
Often narrower, focused on specific substituents |
Broader coverages earlier, narrower later |
| Therapeutic Scope |
Autoimmune, cancers |
Same or expanded indications |
Similar or more specific |
| Method of Use |
Emphasized |
Emphasized |
Confirmed importance of use patents |
Implications for Pharmaceutical Strategy
- Patent Robustness: The broad chemical claims provide significant protection but must be monitored for potential design-arounds.
- Lifecycle Management: Patent expiration in 2022 necessitates focus on patent extensions, formulations, or new uses.
- Freedom to Operate (FTO): Companies developing JAK inhibitors should carefully review claims in the context of this patent’s scope to avoid infringement.
Deep Dive: Key Claims Extracted
Sample Compound Claim (Claim 1):
"A compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, wherein the R groups are as defined..."
Scope: Covers a wide range of derivatives satisfying structural criteria.
Sample Use Claim (Claim 10):
"A method of treating rheumatoid arthritis comprising administering an effective amount of a compound of claim 1."
Scope: Encompasses any regimen using covered compounds for specific indications.
FAQs on Patent US 6,747,019
-
What is the primary therapeutic target of the compounds in this patent?
The compounds inhibit Janus kinases (JAKs), specifically JAK1 and JAK2, key mediators in cytokine signaling pathways involved in autoimmune diseases.
-
Are there biosimilars or generics available post-2022?
Pending patent expiry, biosimilar development is likely to accelerate, potentially leading to generics, contingent on regulatory and patent landscape factors.
-
Can similar compounds with different core structures infringe this patent?
Claims are structurally specific; significantly different core structures outside the claims may not infringe, but close analogs may pose infringement risks.
-
How active is the patent landscape surrounding JAK inhibitors?
Highly active, with multiple patents filed and granted post-2004, reflecting continued innovation and competition in this therapeutic area.
-
What strategic actions should patent holders consider before patent expiry?
Consider pursuing patent extensions, new use patents, formulations, or combination therapies to prolong market exclusivity.
Key Takeaways
-
Scope and Claims: US 6,747,019 broadly claims a class of structurally defined JAK inhibitors suitable for multiple autoimmune and cancer indications. Its compound claims encompass a significant chemical space, while use claims cover therapeutic applications.
-
Patent Landscape: A highly active environment with subsequent patents refining or challenging the scope, including composition, methods, and formulations.
-
Legal and Commercial Implications: The patent's expiry in 2022 signals potential for biosimilar or generic entrants, subject to validation of patent rights. Companies should evaluate patent coverage when developing JAK-targeted therapeutics.
-
Strategic Recommendations: Maintain vigilant patent landscape surveillance, consider filing new patents on improved compounds or formulations, and optimize lifecycle management strategies.
References
- US Patent 6,747,019. "JAK Inhibitors," Innovent Biologics, Inc., June 8, 2004.
- Patent landscape reports on kinase inhibitors, generated by IQVIA and other patent analytics providers.
- FDA approvals relevant to JAK inhibitors, e.g., Xeljanz (tofacitinib), post-2012.
- Patent search and analysis tools utilized, including PatSnap and Google Patents.
This comprehensive review provides a foundation for stakeholders assessing the patent's scope, competitive landscape, and strategic IP management in the evolving JAK inhibitor space.
More… ↓
⤷ Start Trial
|
